Does donation after cardiac death utilization adversely affect hepatocellular cancer survival?

Transplantation

Volumn 100, Issue 9, 2016, Pages 1916-1924

  Khorsandi, Shirin Elizabeth ^a   Yip, Vincent S ^a   Cortes, Miriam ^a   Jassem, Wayel ^a   Quaglia, Alberto ^a   O'Grady, John ^a   Heneghan, Michael ^a   Aluvihare, Varuna ^a   Agarwal, Kosh ^a   Menon, Krishna ^a   Vilca Melendez, Hector ^a   Prachalias, Andreas ^a   Srinivasan, Parthi ^a   Suddle, Abid ^a   Rela, Mohamed ^a   Heaton, Nigel ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; BRAIN DEATH; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR AFTER BRAIN STEM DEATH; DONOR AFTER CARDIAC DEATH; FEMALE; HEALTH CARE UTILIZATION; HEART DEATH; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; ORGAN DONOR; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; TUMOR INVASION; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CELL DIFFERENTIATION; CHI SQUARE DISTRIBUTION; DONOR; DONOR SELECTION; ENGLAND; FACTUAL DATABASE; HEART DISEASE; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SUPPLY AND DISTRIBUTION; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; DONOR SELECTION; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LONDON; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; TUMOR BURDEN; WAITING LISTS;

EID: 84961230924     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001150     Document Type: Article

References (38)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
2. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. J Hepatol. 1999;30:1434-1440.
3. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883.
4. Jay C, Ladner D, Wang E, et al. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant- An analysis of the national registry. J Hepatol. 2011;55:808-813.
5. Jay CL, Skaro AI, Ladner DP, et al. Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: recognizing who can benefit. Liver Transpl. 2012;18:630-640.
6. Grewal HP, Willingham DL, Nguyen J, et al. Liver transplantation using controlled donation after cardiac death donors: An analysis of a large single-center experience. Liver Transpl. 2009;15:1028-1035.
7. Samuel D, Colombo M, El-Serag H, et al. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17(suppl 2):S6-S13.
8. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology. 2004;127:S261-S267.
9. Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant. 2008;8:419-425.
10. van der Bilt, JD, Kranenburg O, Nijkamp MW, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. J Hepatol. 2005;42:165-175.
11. Hubbi ME, Gilkes DM, Hu H, et al. Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cellcycle progression. Proc Natl Acad Sci U S A. 2014;111:E3325-E3334.
12. Davila D, Ciria R, Jassem W, et al. Prediction models of donor arrest and graft utilization in liver transplantation from Maastricht-3 donors after circulatory death. Am J Transplant. 2012;12:3414-3424.
13. Balzan S, Belghiti J, Farges O, et al. The "50-50 criteria" on postoperative day 5: An accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824-828.
14. Ciria R, Davila D, Khorsandi SE, et al. Predictors of early graft survival after pediatric liver transplantation. Liver Transpl. 2012;18:1324-1332.
15. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16:943-949.
16. DeOliveira ML, Jassem W, Valente R, et al. Biliary complications after liver transplantation using grafts from donors after cardiac death: results froma matched control study in a single large volume center. Ann Surg. 2011; 254:716-722.
17. Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using Organ Procurement Transplant Network data. Liver Transpl. 2009;15:859-868.
18. Croome KP, Marotta P, Wall WJ, et al. Should a lower quality organ go to the least sick patient? Model for End-Stage Liver Disease score and donor risk index as predictors of early allograft dysfunction. Transplant Proc. 2012;44:1303-1306.
19. Croome KP, Wall W, Chandok N, et al. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl. 2013;19:1214-1223.
20. Abt PL, Desai NM, Crawford MD, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg. 2004;239:87-92.
21. Selck FW, Grossman EB, Ratner LE, et al. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased donor pool. Ann Surg. 2008;248:599-607.
22. De Vera, ME, Lopez-Solis RC, Dvorchik I, et al. Liver transplantation using donation after cardiac death donors: long- Term follow-up from a single center. Am J Transplant. 2009;9:773-781.
23. Mazzaferro V, Llovet JM, Miceli R, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
24. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4, 000 consecutive patients at a single center. Ann Surg. 2000; 232:490-500.
25. Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-termoutcomes of 3200 liver transplantations over two decades: A single- center experience. Ann Surg. 2005;241:905-916.
26. Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. J Hepatol. 2015;3: 895-904.
27. Vagefi PA, Dodge JL, Yao FY, et al. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015; 21:187-194.
28. Sharma P, Welch K, Hussain H, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci. 2012;57:806-812.
29. Croome KP, Wall W, Quan D, et al. Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts. Hepatobiliary Pancreat Dis Int. 2012; 11:372-376.
30. Croome KP, Lee DD, Burns JM, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. Am J Transplant. 2015;15:1-8.
31. Samoylova ML, Dodge JL, Yao FY, et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014;20:937-944.
32. Schlansky B, Chen Y, Scott DL, et al. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014;20:1045-1056.
33. Roberts JP, Venook A, Kerlan R, et al. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010;16:925-929.
34. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list α- fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814-819.
35. Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19:1108-1118.
36. Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS Natural Geographic Experiment. J Hepatol. 2014; 60:1957-1962.
37. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-2596.
38. Menon KV, Hakeem AR, Heaton N. Review article: liver transplantation for hepatocellular carcinoma- A critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther. 2014;40:893-902.